Natera Q1 2026: A Million Tests, Revenue Rally, and the Long Arc for Signatera

Quarterly results in brief

• Total revenues: $696.6 million in the quarter ended March 31, 2026, up from $501.8 million in Q1 2025 (▲38.8%).
• Gross profit: $450.8 million with a gross margin of 64.7%, vs. 63.1% in the year-ago period, a sign of price discipline and scale benefits.
• Tests processed: ~1,013,600 in Q1 2026, up from ~855,100 in Q1 2025; accessioned ~999,200 of those tests.
• Product mix and volume: Oncology tests ~258,900 (vs ~167,700 in Q1 2025), a 54.4% rise; Women’s Health growth noted as a key quarterly driver.
• Cash flow: Positive cash inflow of about $11.8 million in Q1 2026.
• Operating expenses: $538.6 million in Q1 2026, up 36.0% from $395.9 million a year earlier, reflecting headcount growth and expanded clinical trial activity.
• Intangibles amortization: $5.7 million in Q1 2026; no such amortization in Q1 2025.
• Guidance: 2026 revenue guidance raised by $120 million at the midpoint, from a prior range of $2.62–$2.70 billion to $2.74–$2.82 billion.

What the numbers suggest for Natera and bets across the sector

The headline is volume. Natera processed just over a million tests in a single quarter for the first time, and oncology testing led the charge with a more than 50% year-over-year jump. That kind of volume, paired with a margin that crept up to 64.7%, suggests the business is benefiting from a favorable mix and some optimization in cost of revenues as it scales. In lay terms: the top line is doing fine, and the bench is getting a little lighter under the hood on gross margin.

Yet the operating expense line climbed faster than revenue, up 36% year over year to $538.6 million. The delta is not a blunt instrument; it’s a deliberate investment—staffing for new product offerings, clinical trial activity, and the ramp of R&D and SG&A to support a broader portfolio (notably Signatera and Fetal Focus). The result is an admirable gross margin expansion, but a heavier operating burn in the near term. If you’re thinking in terms of EPS, the current quarter doesn’t provide a pristine read on earnings per share—the press release emphasizes gross margin and revenue flow rather than a clean bottom-line beat or miss. Analysts will be watching for how this translates into an improving EPS trend over the balance of 2026, given the revenue trajectory.

Management’s narrative is that revenue growth is driven by higher volumes and price improvements, with a multi-product push underpinning the trajectory. The ramp in business activity around Signatera and fetal-focused offerings hints at a durable, multi-year growth story rather than a one-off surge from a favorable quarter. In the vocabulary of finance, the company appears to be investing for margin leverage over time—investing now to unlock greater operating leverage as utilization expands and fixed costs normalize.

Outlook: what the new revenue forecast implies for NTRA and peers

The raised 2026 revenue guidance signals management’s confidence in continued demand momentum and pricing power. A midpoint lift of about $60 billion? Not quite—$120 million at the midpoint, translating the same confidence into a higher revenue ceiling. If the trend persists, EPS figures could begin to reflect that levered growth, though the near-term optics will still be shaped by operating expenses and any shifts in test mix.

For sector peers, the message is twofold. First, large actionable cfDNA pipelines embedded in broadening product portfolios can produce outsized revenue gains even when unit economics are still in the process of normalization. Second, the capital-raising vibe around growth initiatives—clinical trials, expanded lab capacity, and new product lines—could compress margins across the sector if competitors chase growth without commensurate gains in scale. In short: volume is currency, but cost discipline remains a necessary ballast.

Executive perspective

“We had an outstanding first quarter, reaching over one million units processed in a single quarter for the first time and delivering strong growth across all areas,” said Steve Chapman, chief executive officer of Natera. “We are seeing the impact of strong 2025 data readouts and innovation translating into increased adoption, particularly for Signatera and Fetal Focus, reinforcing our confidence in the long-term opportunity to transform patient care.”

Takeaways for peers and investors

- The mix shift toward higher-margin testing and new product lines could be a competitive differentiator if sustained. - The combination of revenue growth and a higher operating expense base means near-term profitability remains a function of operating leverage and scale, not just top-line expansion. - A higher revenue forecast sets the bar for the balance of 2026; investors will watch for progression into an EPS trajectory that aligns with the revenue uplift. - Market peers in cfDNA and related diagnostics should consider how Signatera and fetal-focused workflows fare against reimbursement dynamics and the durability of demand in a post-pandemic health landscape.